- Home
- RRR vs VKTX Comparison
RRR vs VKTX Comparison
Compare RRR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- VKTX
- Stock Information
- Founded
- RRR 1976
- VKTX 2012
- Country
- RRR United States
- VKTX United States
- Employees
- RRR N/A
- VKTX N/A
- Industry
- RRR Hotels/Resorts
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- VKTX Health Care
- Exchange
- RRR Nasdaq
- VKTX Nasdaq
- Market Cap
- RRR 3.6B
- VKTX 3.0B
- IPO Year
- RRR 2016
- VKTX 2015
- Fundamental
- Price
- RRR $57.31
- VKTX $32.37
- Analyst Decision
- RRR Buy
- VKTX Strong Buy
- Analyst Count
- RRR 12
- VKTX 12
- Target Price
- RRR $60.25
- VKTX $86.42
- AVG Volume (30 Days)
- RRR 595.6K
- VKTX 5.3M
- Earning Date
- RRR 10-28-2025
- VKTX 10-22-2025
- Dividend Yield
- RRR 3.47%
- VKTX N/A
- EPS Growth
- RRR 3.75
- VKTX N/A
- EPS
- RRR 2.94
- VKTX N/A
- Revenue
- RRR $1,987,845,000.00
- VKTX N/A
- Revenue This Year
- RRR $4.23
- VKTX N/A
- Revenue Next Year
- RRR $3.46
- VKTX N/A
- P/E Ratio
- RRR $19.62
- VKTX N/A
- Revenue Growth
- RRR 7.47
- VKTX N/A
- 52 Week Low
- RRR $35.09
- VKTX $18.92
- 52 Week High
- RRR $63.60
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- RRR 38.88
- VKTX 62.67
- Support Level
- RRR $57.24
- VKTX $25.04
- Resistance Level
- RRR $61.99
- VKTX $32.85
- Average True Range (ATR)
- RRR 1.50
- VKTX 1.49
- MACD
- RRR -0.61
- VKTX 1.01
- Stochastic Oscillator
- RRR 0.36
- VKTX 88.54
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.